Abstract
It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review, we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.
Keywords: Bevacizumab, lung cancer, maintenance, small cell.
Current Cancer Drug Targets
Title:Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Volume: 16 Issue: 3
Author(s): Giandomenico Roviello and Daniele Generali
Affiliation:
Keywords: Bevacizumab, lung cancer, maintenance, small cell.
Abstract: It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review, we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.
Export Options
About this article
Cite this article as:
Roviello Giandomenico and Generali Daniele, Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/1568009616666151106120716
DOI https://dx.doi.org/10.2174/1568009616666151106120716 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of Cathepsin B
Current Medicinal Chemistry Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Prediction of Activities of BRAF (V600E) Inhibitors by SW-MLR and GA-MLR Methods
Current Computer-Aided Drug Design New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Novel Dual Inhibitors of Nuclear Factor-Kappa B (NF-κ B) and Cyclooxygenase- 2 (COX-2): Synthesis, In Vitro Anticancer Activity and Stability Studies of Lantadene–Non Steroidal Anti-inflammatory Drug (NSAID) Conjugates
Current Topics in Medicinal Chemistry Pharmacokinetic Study of Weekly (Days 1-5) Low-dose S-1 in Patients with Non-Small-Cell Lung Cancer
Reviews on Recent Clinical Trials Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Celecoxib A Selective COX-2 Inhibitor Mitigates Fibrosis but not Pneumonitis Following Lung Irradiation: A Histopathological Study
Current Drug Therapy Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Theoretical Analysis of the Binding of Potential Inhibitors to Protein Kinases MK2 and MK3
Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Editorial [Hot Topic: The Therapeutic Potential of Ribonucleases (Guest Editor: Urich Arnold) ]
Current Pharmaceutical Biotechnology Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry